story of the week
Discontinuation of Second- vs First-Line Disease-Modifying Treatment in Middle-Aged Patients With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis
J Neurol 2022 Sep 16;[EPub Ahead of Print], M Chappuis, C Rousseau, E Bajeux, S Wiertlewski, D Laplaud, E Le Page, L Michel, G Edan, A KerbratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.